Candriam Luxembourg S.C.A. Takes $2.24 Million Position in Sierra Oncology Inc (SRRA)

Candriam Luxembourg S.C.A. acquired a new stake in Sierra Oncology Inc (NASDAQ:SRRA) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 600,000 shares of the biotechnology company’s stock, valued at approximately $2,238,000. Candriam Luxembourg S.C.A. owned approximately 1.15% of Sierra Oncology at the end of the most recent quarter.

Separately, Acadian Asset Management LLC grew its stake in Sierra Oncology by 112.3% in the 4th quarter. Acadian Asset Management LLC now owns 32,437 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 17,161 shares in the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

A number of research analysts recently weighed in on SRRA shares. Jefferies Group upgraded shares of Sierra Oncology from a “hold” rating to a “buy” rating in a research note on Monday, October 23rd. Zacks Investment Research lowered shares of Sierra Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, October 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Sierra Oncology currently has a consensus rating of “Hold” and an average target price of $4.00.

Sierra Oncology Inc (SRRA) opened at $2.90 on Tuesday. Sierra Oncology Inc has a one year low of $1.10 and a one year high of $4.09. The firm has a market cap of $151.66 and a P/E ratio of -3.05.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at

Sierra Oncology Profile

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Institutional Ownership by Quarter for Sierra Oncology (NASDAQ:SRRA)

Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with's FREE daily email newsletter.

Leave a Reply